Shares of Lantheus and Point Biopharma Plummet on Disappointing Prostate Cancer Treatment Data
Shares of Lantheus Holdings Inc. and Point Biopharma Global Inc. dropped after releasing data from a trial of their experimental prostate cancer treatment, Lu-PNT2002. The therapy showed a median progression-free survival of 9.5 months, compared to six months for patients on an alternative treatment. Investors were comparing the results to Novartis AG's Pluvicto, which had a median progression-free survival of 12 months. Lantheus stock fell 20% premarket, while Point Biopharma shares fell 10.9%.